Randomized-controlled trial of sacubitril/valsartan and amlodipine combination in Japanese uncontrolled hypertensive patients (J-SAMIT).
Kazuomi Kario, Hiromi Rakugi, Chiyo Ito et al.
✦ AI-curated · Sources linked
In 30 seconds
This multicenter, randomized, double-blind trial evaluated the efficacy of sacubitril/valsartan (SacVal) combined with amlodipine (AML) in Japanese patients with grade I/II hypertension inadequately controlled by SacVal monotherapy. The study involved 717 patients and found that all combinations of SacVal and AML achieved significant reductions in mean sitting systolic blood pressure (msSBP) compared to SacVal alone, with the highest combination showing a treatment difference of -16.39 mmHg (p < 0.001).
Key findings
- Combination therapy with SacVal and AML achieved msSBP reductions of -5.63, -12.94, and -16.39 mmHg compared to SacVal monotherapy.
- 24-hour ambulatory SBP reductions were -6.48, -14.18, and -17.70 mmHg for the respective combinations.
- BP control rates improved to 57.2%, 72.5%, and 79.9% with combination therapy versus 35.0% with SacVal alone.
- The safety profile of the combination therapy was similar to that of SacVal monotherapy.
Why it matters
Effective blood pressure management is crucial in preventing cardiovascular events. This study highlights the potential of combining SacVal with AML to enhance blood pressure control in patients who do not respond adequately to SacVal alone, offering a viable treatment strategy.